預告訂定使用原料「印度仙人掌(Caralluma fimbriata)萃取粉」之每日食用限量及應標示警語草案 (TFDA發布日期2011-12-02) 行政院衛生署 公告 發文日期：中華民國100年12月2日 發文字號：署授食字第1001303654號 主旨：預告訂定使用原料「印度仙人掌(Caralluma fimbriata)萃取粉」之每日食用限量及應標示警語草案。依據：行政程序法第一百五十四第一項。公告事項：一、訂定機關：行政院衛生署。二、訂定依據：食品衛生管理法第十七條第一項第六款。三、原料「印度仙人掌萃取粉」之每日食用限量為50 mg。四、使用原料「印度仙人掌萃取粉」之包裝食品，應以中文顯著標示「孕婦及嬰幼兒不宜食用」等字樣。五、本案另載於本署食品藥物管理局網站（網址：http://www.fda.gov.tw）之「公告資訊」下之「本局公告」網頁及本署網站（網址：http://www.doh.gov.tw）。
Antiobesogenic and Antiatherosclerotic Properties of Caralluma fimbriata Extract.
(J Nutr Metab. 2010;2010:285301. Epub 2010 Dec 28.)
There is evidence that the principles present in the widely consumed Indian food plant C. fimbriata extract (CFE) suppress appetite, and provide antiobesogenic and metabolic benefits. The Diet-Induced Obesity (DIO) rat model was used to investigate CFE's anorexigenic effects. Rats were randomly divided into three groups: (i) untreated control (C), (ii) control for cafeteria diet (CA), and (iii) cafeteria diet fed + CFE treated. Rats in the test group received cafeteria diet and CFE from day one onwards. CFE was administered by gavage at three doses (25, 50, 100 mg/Kg BW per day) for 90 days. The antiobesogenic effects of CFE were evaluated by monitoring changes in feed intake, body weight, serum lipid and hormonal (leptin) profiles, fat pads, and liver weight. Antiatherosclerotic effects were measured by histology. CFE induced significant and dose-dependent inhibition of food intake, with dose-related prevention of gains in body weight, liver weight, and fat pad mass. Alterations in serum lipid profiles associated with weight gain were similarly inhibited, as were the typical increases in serum leptin levels. These data substantiate CFE's reported anorexigenic effects. CFE treatment also conferred protection against atherogenesis. We conclude that CFE possesses antiobesogenic and antiatherosclerotic properties.
Posts
No comments:
Post a Comment